Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€133.26

€133.26

0.790%
1.04
0.790%
€169.00
 
14:08 / Tradegate WKN: 853260 / Symbol: JNJ / Name: Johnson & Johnson / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Johnson & Johnson Stock

The Johnson & Johnson stock is trending slightly upwards today, with an increase of €1.04 (0.790%) compared to yesterday's price.
With 33 Buy predictions and not a single Sell prediction Johnson & Johnson is an absolute favorite of our community.
As a result the target price of 169 € shows a positive potential of 26.82% compared to the current price of 133.26 € for Johnson & Johnson.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Johnson & Johnson stock. Negative votes have not been in the majority for any criteria for this stock

Johnson Johnson is a multinational company that focuses on the development, manufacturing, and marketing of a wide range of consumer health products, medical devices, and pharmaceuticals. The company was founded in 1886 and is headquartered in New Jersey, USA. It operates in more than 60 countries and has a diverse portfolio of popular brands including Band-Aid, Tylenol, and Neutrogena. As of 2021, Johnson Johnson has a market capitalization of over $435 billion and is listed on the New York Stock Exchange under the symbol JNJ.

Pros and Cons of Johnson & Johnson in the next few years

Pros
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Johnson & Johnson vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Johnson & Johnson 0.790% 0.885% -3.079% -2.993% -4.932% -23.190% 6.013%
Elanco Animal Health Inc. 2.990% 6.138% 2.753% -6.735% 6.010% -34.633% -35.228%
Pfizer Inc. 0.920% 1.433% 2.808% -19.243% -16.299% -57.699% -25.642%
Biogen Inc. 0.950% 1.379% -3.457% -48.912% -23.429% -45.396% -53.134%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-14

Johnson & Johnson, symbolized as JNJ, holds a prominent position in the Pharmaceutical industry. Reviewing their financial data indicate robust financial base and promising trends over the years. Their capacity to generate revenues and maintain substantial margins underscores their operational efficiency. On the flip side, the high levels of liabilities and debts might raise some eyebrows. The analysis below explores these aspects in depth.

Reflecting upon the income statement for the years 2020, 2021 and 2022, it's clear that JNJ has shown consistent growth in net income. For instance, in 2022, the net income was listed at $17.94 billion compared to $14.71 billion in 2020. Not just the net income, even the gross profit has shown positive trends, increasing from $54.15 billion in 2020 to $63.85 billion in 2022, reinforcing their capacity to improve operational efficiency and drive profits.

The cash flow statements for the corresponding years paint a similar picture. The total cash from operating activities for 2022 was $21.19 billion as compared to $23.53 billion in 2020. While there was a slight drop, the numbers clearly indicate that Johnson & Johnson has maintained substantial cash flow from its main line of business.

Comments

Prediction Buy
Perf. (%) -0.82%
Target price 158.538
Change
Ends at 05.06.26

Johnson & Johnson (NYSE: JNJ) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $181.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -1.93%
Target price 159.805
Change
Ends at 16.04.26

Johnson & Johnson (NYSE: JNJ) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $181.00 price target on the stock.
Ratings data for JNJ provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -1.72%
Target price 142.268
Change
Ends at 14.04.26

Johnson & Johnson (NYSE: JNJ) had its price target lowered by analysts at Raymond James from $165.00 to $162.00. They now have an "outperform" rating on the stock.
Ratings data for JNJ provided by MarketBeat
Show more

News

Johnson & Johnson Stock: Cancer Breakthroughs Spark Mixed Market Reactions
Johnson & Johnson Stock: Cancer Breakthroughs Spark Mixed Market Reactions

Johnson & Johnson is generating significant attention in both medical and financial circles following impressive study results for its multiple myelom treatments. The pharmaceutical giant's cancer

Johnson & Johnson Stock: Acquisition Progress Amid Talc Setback
Johnson & Johnson Stock: Acquisition Progress Amid Talc Setback

Johnson & Johnson is advancing toward completing its strategic acquisition of Intra-Cellular Therapies, expected to finalize around April 2, 2025, following shareholder approval on March 27. The

Johnson & Johnson Stock: Court Setback Triggers Financial Shift
Johnson & Johnson Stock: Court Setback Triggers Financial Shift

Johnson & Johnson (J&J) faces a significant legal defeat as a US bankruptcy court in Texas rejected its subsidiary Red River Talc LLC's proposed settlement plan. This plan, valued at approximately